Compositions for pre-surgical nutritional supplements
US-2024189256-A1 · Jun 13, 2024 · US
Chemotherapeutic drug combination
US9737566B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9737566-B2 |
| Application number | US-201515114854-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 14, 2015 |
| Priority date | Jan 30, 2014 |
| Publication date | Aug 22, 2017 |
| Grant date | Aug 22, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a chemotherapeutic drug combination containing heterodinuclear Cu (II)-Mn(II) complex. The objective of the present invention is to provide a drug combination, which will be actively used in chemotherapy, is anticarcinogenic and has no side effects, facilitates penetration into the cell, shows selectivity only for cancer cells and does not harm healthy cells, and is not toxic for the tissues and organs in the body, and which can prepared easily and provides a definitive and fast treatment.
First claim
Opening claim text (preview).
The invention claimed is: 1. A chemotherapeutic drug combination comprising a combination of a polynuclear Schiff base complex and a pluronic; wherein the polynuclear Schiff base complex is heterodinuclear Cu (II)-Mn(I) complex; wherein the pluronic is P85; wherein the combination of the polynuclear Schiff base complex and the pluronic enables penetration of the chemotherapeutic drug combination selectively for cancer cells while increasing viability in healthy cells. 2. The chemotherapeutic drug combination according to claim 1 , a concentration of the polynuclear Schiff base complex is 0.5 mg/Kg or less. 3. The chemotherapeutic drug combination according to claim 1 , a concentration of the polynuclear Schiff base complex is 0.5 mg/Kg. 4. A chemotherapeutic drug combination, consisting of a combination of a polynuclear Schiff base complex and a pluronic; wherein the polynuclear Schiff base complex is heterodinuclear Cu (II)-Mn(I) complex; wherein the pluronic is selected from at least one of F68, P106, P407, P85, and P123.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9737566B2 cover?
- The present invention relates to a chemotherapeutic drug combination containing heterodinuclear Cu (II)-Mn(II) complex. The objective of the present invention is to provide a drug combination, which will be actively used in chemotherapy, is anticarcinogenic and has no side effects, facilitates penetration into the cell, shows selectivity only for cancer cells and does not harm healthy cells, an…
- Who is the assignee on this patent?
- Yeditepe Üniversitesi, Univ Yeditepe
- What technology area does this patent fall under?
- Primary CPC classification A61K33/34. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 22 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).